eFFECTOR Therapeutics, Inc.

eFFECTOR Therapeutics, Inc. filed an 8-K with the SEC on August 24, 2021 (accession 0001193125-21-255206) in connection with its business combination with Locust Walk Acquisition Corp., trading on Nasdaq under the ticker LWAC. LWAC was a blank-check company sponsored by Locust Walk, a life sciences-focused advisory and investment banking firm, and completed its IPO in 2020 targeting the healthcare and biopharmaceutical sector. eFFECTOR Therapeutics is a clinical-stage oncology company focused on translation regulation as a therapeutic approach to treating cancer. The 8-K filing reflects activity surrounding the de-SPAC transaction that brought eFFECTOR to the public markets. Sign up at SpacDesk for complete filing data, deal timelines, and deep SPAC analytics.